Rosandra N. Kaplan

About

I am a physician scientist with particular interest in pediatric oncology and understanding the process of metastasis and the role of the metastatic tumor microenvironment in metastatic progression.

Employment

• National Cancer Institute Principal Investigator
  2010 - Present
• NewYork-Presbyterian Hospital/Weill Cornell Medical Center Assistant Professor
  2006 - 2010
• Columbia University Medical Center Attending Physician
  2001 - 2002

Education

• Memorial Sloan-Kettering Cancer Center Pediatric Hematology/Oncology Fellowship
  2002 - 2006
• Boston Children's Hospital Residency
  1998 - 2001
• Dartmouth College Geisel School of Medicine MD
  1994 - 1998

Projects & Funding

Projects & funding information is unavailable.

Publications (88)

• Supplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
  2025 DOI: 10.1158/1078-0432.30709438
  +Save
• Data from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
  2025 DOI: 10.1158/1078-0432.c.6747873
  +Save
• A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
  Cancer Research Communications 2025 DOI: 10.1158/2767-9764.CRC-25-0293
  +Save
• Table 6 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
  2025 DOI: 10.1158/2767-9764.30093312
  +Save
• Table 5 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
  2025 DOI: 10.1158/2767-9764.30093315
  +Save
• Table 4 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
  2025 DOI: 10.1158/2767-9764.30093318
  +Save
• Table 3 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
  2025 DOI: 10.1158/2767-9764.30093321
  +Save
• Table 2 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
  2025 DOI: 10.1158/2767-9764.30093324
  +Save
• Table 1 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
  2025 DOI: 10.1158/2767-9764.30093327
  +Save
• Supplementary Table 4 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
  2025 DOI: 10.1158/2767-9764.30093330
  +Save